BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22130450)

  • 1. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
    Takahashi M; Katagiri T; Furuya H; Hohjoh H
    Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
    Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
    Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1
    Maruyama R; Nguyen Q; Roshmi RR; Touznik A; Yokota T
    Nucleic Acid Ther; 2022 Jun; 32(3):185-193. PubMed ID: 35085461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting.
    Kaplan J; Kaplan FS; Shore EM
    Gene Ther; 2012 Jul; 19(7):786-90. PubMed ID: 22011642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients.
    Carvalho DR; Navarro MM; Martins BJ; Coelho KE; Mello WD; Takata RI; Speck-Martins CE
    Clin Genet; 2010 Feb; 77(2):171-6. PubMed ID: 19796185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of the noggin (NOG) and of the activin A type I receptor (ACVR1) genes in a series of twenty-seven French fibrodysplasia ossificans progressiva (FOP) patients.
    Lucotte G; Houzet A; Hubans C; Lagarde JP; Lenoir G
    Genet Couns; 2009; 20(1):53-62. PubMed ID: 19400542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classical and atypical Fibrodysplasia Ossificans Progressiva in India.
    Madhuri V; Santhanam M; Sugumar LK; Rajagopal K; Chilbule SK
    Ann Hum Genet; 2015 Jul; 79(4):245-52. PubMed ID: 26058333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
    Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
    Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
    Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
    J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drosophila models of FOP provide mechanistic insight.
    Le V; Anderson E; Akiyama T; Wharton KA
    Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACVR1 gene mutations in four Turkish patients diagnosed as fibrodysplasia ossificans progressiva.
    Eresen Yazıcıoğlu C; Karatosun V; Kızıldağ S; Ozsoylu D; Kavukçu S
    Gene; 2013 Feb; 515(2):444-6. PubMed ID: 23260810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene.
    Cappato S; Traberg R; Gintautiene J; Zara F; Bocciardi R
    Mol Genet Genomic Med; 2021 Oct; 9(10):e1774. PubMed ID: 34347384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with ACVR1
    Kou S; De Cunto C; Baujat G; Wentworth KL; Grogan DR; Brown MA; Di Rocco M; Keen R; Al Mukaddam M; le Quan Sang KH; Masharani U; Kaplan FS; Pignolo RJ; Hsiao EC
    Orphanet J Rare Dis; 2020 Jul; 15(1):193. PubMed ID: 32727600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.